DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on October 14, 2004; DOI: 10.1124/dmd.104.001578


0090-9556/05/3301-157-164$20.00
DMD 33:157-164, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.104.001578v1
33/1/157    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hazai, E.
Right arrow Articles by Kupfer, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hazai, E.
Right arrow Articles by Kupfer, D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*METHOXYCHLOR

INTERACTIONS BETWEEN CYP2C9 AND CYP2C19 IN RECONSTITUTED BINARY SYSTEMS INFLUENCE THEIR CATALYTIC ACTIVITY: POSSIBLE RATIONALE FOR THE INABILITY OF CYP2C19 TO CATALYZE METHOXYCHLOR DEMETHYLATION IN HUMAN LIVER MICROSOMES

Eszter Hazai, and David Kupfer

Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts

Previous studies in our laboratory showed that among cDNA-expressed human cytochrome P450 (P450) supersomes, CYP2C19 was the most active in methoxychlor-O-demethylation (Hu et al., 2004). However, based on the lack of inhibition of methoxychlor-O-demethylation by monoclonal anti-CYP2C19 antibodies in human liver microsomes (HLM), CYP2C19 did not seem to catalyze that reaction in HLM. By contrast, CYP2C9, much less active than CYP2C19 in supersomes, was the most active in HLM. The current study examines whether the lack of methoxychlor-O-demethylation by CYP2C19 in HLM was due to CYP2C19 exhibiting inferior competition for the NADPH-cytochrome P450 reductase (CPR) versus CYP2C9 and explores the interactions between CYP2C9 and CYP2C19 in a singular and binary complex of a reconstituted system. When reconstituted with CPR, cytochrome b5, and lipid, purified CYP2C19 and CYP2C9 catalyzed methoxychlor-O-demethylation. However, whereas equimolar CPR to CYP2C9 supported maximal rates of methoxychlor demethylation and diclofenac hydroxylation, the rate of methoxychlor demethylation by CYP2C19 was not fully saturated, even with a 9-fold molar excess of CPR over CYP2C19. This behavior of CYP2C19 was also observed with S-mephenytoin as the substrate. When a binary reconstitution system was prepared by mixing CYP2C9 and CYP2C19 enzymes, methoxychlor-O-demethylation and S-mephenytoin hydroxylation by CYP2C19 were dramatically inhibited. Inhibition depended on the amount of CPR and substrate used. By contrast, in the incubation containing CYP2C9, diclofenac hydroxylation was activated by the presence of CYP2C19. These results show that interactions among P450 enzymes can modulate their catalytic rates, which depend on the substrate undergoing metabolism.


Address correspondence to: Dr. David Kupfer, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605. E-mail: david.kupfer{at}umassmed.edu




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
M. Subramanian, M. Low, C. W. Locuson, and T. S. Tracy
CYP2D6-CYP2C9 Protein-Protein Interactions and Isoform-Selective Effects on Substrate Binding and Catalysis
Drug Metab. Dispos., August 1, 2009; 37(8): 1682 - 1689.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Ouellet, L. M. Podust, and P. R. O. de Montellano
Mycobacterium tuberculosis CYP130: CRYSTAL STRUCTURE, BIOPHYSICAL CHARACTERIZATION, AND INTERACTIONS WITH ANTIFUNGAL AZOLE DRUGS
J. Biol. Chem., February 22, 2008; 283(8): 5069 - 5080.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
F. T. Peters, M. R. Meyer, D. S. Theobald, and H. H. Maurer
Identification of Cytochrome P450 Enzymes Involved in the Metabolism of the New Designer Drug 4'-Methyl-{alpha}-pyrrolidinobutyrophenone
Drug Metab. Dispos., January 1, 2008; 36(1): 163 - 168.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
L. D. Stuchal, K. M. Kleinow, J. J. Stegeman, and M. O. James
DEMETHYLATION OF THE PESTICIDE METHOXYCHLOR IN LIVER AND INTESTINE FROM UNTREATED, METHOXYCHLOR-TREATED, AND 3-METHYLCHOLANTHRENE-TREATED CHANNEL CATFISH (ICTALURUS PUNCTATUS): EVIDENCE FOR ROLES OF CYP1 AND CYP3A FAMILY ISOZYMES
Drug Metab. Dispos., June 1, 2006; 34(6): 932 - 938.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.